
Tali Azenkot, MD, discusses the rationale for combining dupilumab with cemiplimab in early-stage, resectable non–small cell lung cancer.

Your AI-Trained Oncology Knowledge Connection!

Tali Azenkot, MD, is a fellow of hematology and oncology at the University of California San Diego Health.

Published: July 7th 2025 | Updated: